A Phase II Trial of Tislelizumab in combination with Sitravatinib for Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy.
The ITTACc study is an ANZGOG-developed trial led in Australia by A/Prof Jeffrey Goh from the Royal Brisbane and Women’s Hospital. The study will be opening at 12 sites across Australia and New Zealand, with ANZGOG incorporating its first teletrial cluster in Queensland.
Teletrials build on the telehealth model of delivering health care and providing a way to increase access to clinical trials for patients living in regional, rural, and remote locations, whilst reducing the disparity in patient outcomes for geographically dispersed populations.
Teletrials build on the telehealth model of delivering health care and providing a way to increase access to clinical trials for patients living in regional, rural, and remote locations, whilst reducing the disparity in patient outcomes for geographically dispersed populations.
Incorporating a teletrial cluster into the ITTACc study will enable patients living in regional parts of Queensland to participate in the study closer to where they live.
With the guidance and support of the Queensland Regional Clinical Trials Coordinating Centre (QRCCC) and The Australian Teletrial Program (ATP), as well as the significant contribution and efforts of the primary site – Royal Brisbane and Women’s Hospital – in supporting the satellite sites, Mackay Hospital and Townsville Hospital, ATP grant funding was applied to the trial to enable the teletrial model.
The study will open to recruitment in early July 2023 for eligible patients with recurrent cervical cancer.
Want to know more about ANZGOG’s clinical trials?
To find out more about ANZGOG’s clinical trials, click here.
